InnoCare is building a pipeline of drug candidates to target autoimmune diseases and cancers that are prevalent in China. The targets were chosen based on our proprietary cancer genomics insights in order to provide safe and effective targeted- and immuno-therapies for patients with unmet medical needs. We are interested in small molecules and biologics. Currently we have multiple compounds under development designed for stand-alone and/or combination treatments.